KAMADA » ABOUT US » COMPANY PROFILE

COMPANY PROFILE

Kamada is focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company’s flagship product is GLASSIA®, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership with Baxalta (now part of Shire plc) and in other counties through local distributors, for the indication of Alpha-1 Antitrypsin Deficieny (AATD).

Kamada aims to become the innovator in the AATD field by developing different therapeutic approaches to AATD independently, or through collaborations with strategic partners. In addition, the company develops additional indications for AAT, such as GvHD, Type-1 Diabetes and lung transplantation rejection. Such development programs are intended to be performed through strategic collaborations, and as such are pursued to the point of developing sufficient data to potentially attract strategic partners.

In addition to GLASSIA®, Kamada has a product line of six additional plasma-derived pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia.

Kamada's rabies immune globulin (Human) product received FDA approval for Post-Exposure Prophylaxis against rabies infection and is marketed in the U.S. through a partnership with Kedrion Biopharma.

Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.

Founded in 1990, Kamada is listed on NASDAQ since 2013 and Tel-Aviv stock exchange since 2005 (KMDA). Kamada's headquarters is located in the Weizmann Science Park in Rehovot, Israel, and its manufacturing facility is located in Beit Kama, Israel.